Want to see GB:TSTL full AI Analyst Report?
TSTL Stock Chart & Stats
425.00 p
2.50 p(0.59%)
At close: 4:00 PM EST
425.00 p
2.50 p(0.59%)
Day’s Range― - ―
52-Week Range350.00 p - 445.00 p
Previous CloseN/A
Volume2.07K
Average Volume (3M)75.90K
Market Cap
£191.99M
Enterprise Value183.55M
Total Cash (Recent Filing)£13.29M
Total Debt (Recent Filing)£5.82M
Price to Earnings (P/E)24.3
Beta0.69
Next Earnings
Oct 19, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield3.48%
Share Statistics
EPS (TTM)0.16
Shares Outstanding47,997,290
10 Day Avg. Volume83,961
30 Day Avg. Volume75,902
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.93
Price to Sales (P/S)4.21
P/FCF Ratio20.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)£56.30M
Bulls Say, Bears Say
Bulls Say
High Gross & EBITDA MarginsSustained high gross margins (~81.6%) and a 29% adjusted EBITDA margin reflect durable pricing power from proprietary chlorine dioxide chemistry and efficient operations. This margin base supports reinvestment, dividend policy and buffers against cyclical volume swings over a multi‑year horizon.
Recurring Consumables & Regulatory ValidationRevenue is anchored in repeat‑purchase consumables and validated infection‑control processes, creating predictable, recurring demand. Clinical guideline inclusions and compatibility with >1,200 probes increase switching costs and long‑term adoption across hospital departments and geographies.
Strong Balance Sheet And Cash GenerationA debt‑free balance sheet with robust cash balances and strong operating cash generation provides financial flexibility to fund U.S. commercial rollouts, clinical studies, and insourcing investments without undue leverage, supporting medium‑term growth and progressive dividends.
Bears Say
Free Cash Flow Growth DeclineA 12.7% decline in free cash flow growth signals early softening in cash conversion that could constrain discretionary spending, dividend increases or acquisitions if it persists. Monitoring is needed to ensure investment and dividend plans remain sustainable over the medium term.
China / APAC Market WeaknessMaterial weakness in China/APAC exposes Tristel to regional demand volatility and policy risk. Reliance on recovering emerging markets could slow aggregate revenue growth and require reallocation of commercial resources or pricing adjustments to offset prolonged regional headwinds.
Margin Pressure From Insourcing & Higher Operating SpendInsourcing wipes and associated asset costs, plus a one‑off GBP 300k write‑off and higher S&M and hiring, raise fixed cost and execution risk. If scale benefits are delayed, these structural cost increases could compress margins and slow target EBITDA delivery in the medium term.
Tristel News
TSTL FAQ
What was Tristel PLC’s price range in the past 12 months?
Tristel PLC lowest share price was 350.00 p and its highest was 445.00 p in the past 12 months.
What is Tristel PLC’s market cap?
Tristel PLC’s market cap is £191.99M.
When is Tristel PLC’s upcoming earnings report date?
Tristel PLC’s upcoming earnings report date is Oct 19, 2026 which is in 106 days.
How were Tristel PLC’s earnings last quarter?
Tristel PLC released its earnings results on Mar 02, 2026. The company reported 0.094 p earnings per share for the quarter, beating the consensus estimate of 0.092 p by 0.002 p.
Is Tristel PLC overvalued?
According to Wall Street analysts Tristel PLC’s price is currently Overvalued.
Does Tristel PLC pay dividends?
Tristel PLC pays a Semiannually dividend of 0.057 p which represents an annual dividend yield of 3.48%. See more information on Tristel PLC dividends here
What is Tristel PLC’s EPS estimate?
Tristel PLC’s EPS estimate is 0.09.
How many shares outstanding does Tristel PLC have?
Tristel PLC has 47,997,290 shares outstanding.
What happened to Tristel PLC’s price movement after its last earnings report?
Tristel PLC reported an EPS of 0.094 p in its last earnings report, beating expectations of 0.092 p. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of Tristel PLC?
Currently, no hedge funds are holding shares in GB:TSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tristel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.08%
12-Months-Change
Fundamentals
Return on Equity
23.64%
Trailing 12-Months
Asset Growth
6.03%
Trailing 12-Months
Company Description
Tristel PLC
Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core divisions: the decontamination of medical devices within hospital environments, the disinfection of hospital-based environmental surfaces, and an additional 'Other' category. The firm offers an extensive range of disinfection solutions for medical instruments under its Tristel brand. These solutions are applied across a wide spectrum of clinical areas, including airway management, cardiology, ear, nose and throat (ENT), endoscopy, gastrointestinal physiology, laboratory applications, ophthalmology, phlebotomy, reproductive health/IVF, general surface disinfection, ultrasound, urology, and women's health, alongside other specialized products. Tristel plc was established in 1993 and has its main office situated in Snailwell, United Kingdom.
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
CVS Group plc
―
Surgical Innovations
―
Smith & Nephew
―
Options Prices
Currently, No data available
---